CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine
CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine
复制标题
DOI：
10.1016/j.vaccine.2007.12.027
复制
发表时间：
2008-02-26
期刊：
影响因子：
5.5
通讯作者：
Lycke, Nits
中科院分区：
文献类型：
--
作者：
Eliasson, Dubravka Grdic;El Bakkouri, Karim;Lycke, Nits
目前，针对潜在的大流行性流感病毒感染的候选疫苗寥寥无几。我们提供了令人信服的证据，证明基于CTA1-DD佐剂并包含基质蛋白2(M2e)胞外结构域表位串联重复的靶向融合蛋白CTA1-3M2e-DD对小鼠的潜在致命挑战流感病毒感染具有强大的保护性免疫。该制剂对粘膜免疫高度有效，并能促进高水平的WE特异性血清免疫球蛋白G和粘膜免疫球蛋白A抗体滴度，以及一种迄今未知的抗WE CD4T细胞免疫。这种新型的CTA1-3M2e-DD融合蛋白结合了佐剂和保守的甲型流感抗原，有望成为一种通用的抗流感疫苗。(C)2008爱思唯尔有限公司。保留所有权利。
At present few vaccine candidates exists against potentially pandemic influenza virus infections. We provide compelling evidence that a targeted fusion protein based on the CTA1-DD adjuvant and containing tandem repeats of the matrix protein 2 (M2e) ectodomain epitope, CTA1-3M2e-DD, confers strong protective immunity against a potentially lethal challenge infection with influenza virus in mice. The formulation was highly effective for mucosal immunizations and promoted high We-specific serum IgG and mucosal IgA antibody titers and an hitherto unknown anti-We CD4 T cell immunity. This novel CTA1-3M2e-DD fusion protein combines adjuvant and a conserved influenza A antigen in a promising candidate for a universal anti-influenza vaccine. (C) 2008 Elsevier Ltd. All rights reserved.